| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/08/2009 | WO2009004914A1 Pet probe having alkoxy group substituted by fluorine and hydroxy group |
| 01/08/2009 | WO2009004650A1 Novel substituted piperidones as hsp inducers |
| 01/08/2009 | WO2009004584A1 3-aza-bicyclo[3.3.0]octane compounds |
| 01/08/2009 | WO2009004430A1 N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| 01/08/2009 | WO2009004146A2 Novel herbimycin a analogue derivatives, compositions containing same and use thereof |
| 01/08/2009 | WO2009004082A2 Anticonvulsive pharmaceutical compositions |
| 01/08/2009 | WO2009004071A1 Use of piperine and derivatives thereof for the therapy of neurological conditions |
| 01/08/2009 | WO2009004038A2 Pirenzepine and derivatives thereof as anti-amyloid agents |
| 01/08/2009 | WO2009003993A1 Piperidine derivatives useful as orexin receptor antagonists |
| 01/08/2009 | WO2009003868A2 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| 01/08/2009 | WO2009003867A1 4-imidazolines and their use as antidepressants |
| 01/08/2009 | WO2009003255A1 Pharmaceutical compositions comprising semicarbazones and thiosemicar-bazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms |
| 01/08/2009 | WO2009003226A1 Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration |
| 01/08/2009 | WO2008142693A3 Regulation of myelination by nectin-like (necl) molecules |
| 01/08/2009 | WO2008125891A3 Pyrimidinyl-piperazines useful as dopamine d3 /d2 receptor ligands |
| 01/08/2009 | WO2008119720A8 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine |
| 01/08/2009 | WO2008080001A3 Compounds and methods for kinase modulation, and indications therefor |
| 01/08/2009 | WO2008039863A3 Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| 01/08/2009 | US20090012270 Ox2 receptor homologs |
| 01/08/2009 | US20090012182 Crystal forms of O-desmethylvenlafaxine succinate |
| 01/08/2009 | US20090012180 Sustained release oral dosage forms; analgesics |
| 01/08/2009 | US20090012179 Use of Tyrphostins to Stimulate Neurite Outgrowth |
| 01/08/2009 | US20090012178 Benzoxazocines and Their Therapeutic Use |
| 01/08/2009 | US20090012177 Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs |
| 01/08/2009 | US20090012176 Process for manufacturing entacapone |
| 01/08/2009 | US20090012170 Treatment of symptoms of motor dysfunction |
| 01/08/2009 | US20090012160 such as 15-Ethoxycarbonyl-3,3,14,14-tetramethylpentadecanoyl-L-carnitine, for the treatment of cardiovascular, metabolic and gastrointestinal disorders, inflammation, cancer, anemia, Alzheimer's disease, modulating peroxisome proliferator-activated receptors, as microbiocides and viricides |
| 01/08/2009 | US20090012153 Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase n inhibitors |
| 01/08/2009 | US20090012149 Prodrug of an ice inhibitor |
| 01/08/2009 | US20090012147 2-(4-Chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; for treating, ameliorating, or inhibiting the effects of movement disorders and/or motor fluctuations in a subject suffering from Parkinson's disease |
| 01/08/2009 | US20090012139 Amino-5-[4-(difluoromethoxy) phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase |
| 01/08/2009 | US20090012127 Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators |
| 01/08/2009 | US20090012122 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/08/2009 | US20090012118 Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni |
| 01/08/2009 | US20090012117 Bicyclic derivatives as modulators of ion channels |
| 01/08/2009 | US20090012112 Alpha 1A-adrenoceptor antagonists |
| 01/08/2009 | US20090012110 Morphine compounds for pharmaceutical compositions |
| 01/08/2009 | US20090012101 Mucarinic Agonists and Methods of Use Thereof |
| 01/08/2009 | US20090012099 Novel Compounds |
| 01/08/2009 | US20090012098 5-ht1a receptor subtype agonist |
| 01/08/2009 | US20090012095 Human n-type calcium channel blockers |
| 01/08/2009 | US20090012093 Receptor Function Regulator |
| 01/08/2009 | US20090012089 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators |
| 01/08/2009 | US20090012088 Compounds for the Treatment of Neurodegeneration and Stroke |
| 01/08/2009 | US20090012083 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/08/2009 | US20090012081 Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells |
| 01/08/2009 | US20090012074 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor |
| 01/08/2009 | US20090012073 N-aroyl cyclic amines |
| 01/08/2009 | US20090012062 Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases |
| 01/08/2009 | US20090012059 Dipeptidyl peptidase inhibitors |
| 01/08/2009 | US20090012056 Quinoline Compounds Capable of Binding the Cb2 and/or the 5-Ht6 Receptor |
| 01/08/2009 | US20090012040 Biocompatible polymers, process for their preparation and compositions containing them |
| 01/08/2009 | US20090012039 Use of methylcobalamin nasal spray to treat disorders |
| 01/08/2009 | US20090012036 Stable S-adenosyl-L-methionine |
| 01/08/2009 | US20090012011 Novel Compounds |
| 01/08/2009 | US20090012010 Amino acid derivatives as calcium channel blockers |
| 01/08/2009 | US20090011995 Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer |
| 01/08/2009 | US20090011986 Thiosuccinic Acid Derivatives and the Use Thereof |
| 01/08/2009 | US20090011985 Gh secretagogues and uses thereof |
| 01/08/2009 | US20090011980 Method of Treating Parkinson's Disease in Humans by Direct Infusion of Glial Cell-Line Derived Neurotrophic Factor Into the Zona Incerta |
| 01/08/2009 | US20090011058 Standardized extract of the peppercorns from the plant zanthoxylum pipertium(Hua Jiao or Sansho) used to manage, treat and/or reverse autism, autism, spectrum disorders, autistic-like symptoms, Fragile-X, and/or Fragile-X symptoms (FXS) by seleltively blocking and halting the enzymatic activity of the kinase PAK |
| 01/08/2009 | US20090011030 Breakthrough pain management |
| 01/08/2009 | US20090011015 Method for promoting sleep |
| 01/08/2009 | US20090011010 Controlled release and taste masking oral pharmaceutical composition |
| 01/08/2009 | US20090010992 Drug formulations for oral transmucosal delivery to pediatric patients |
| 01/08/2009 | US20090010986 Polymeric gel delivery system for pharmaceuticals |
| 01/08/2009 | US20090010909 Novel GPCR and methods of use of the same |
| 01/08/2009 | US20090010895 Isolated cells and populations comprising same for the treatment of CNS diseases |
| 01/08/2009 | US20090010894 Methods and systems for identifying compounds that modulate alpha-synuclein aggregation |
| 01/08/2009 | US20090010873 Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis |
| 01/08/2009 | US20090010839 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |
| 01/08/2009 | DE202008007463U1 Nikotinteebeutel Nicotine teabag |
| 01/08/2009 | CA2729006A1 Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration |
| 01/08/2009 | CA2699965A1 Pet probe having an alkoxy group substituted by fluorine and hydroxy group |
| 01/08/2009 | CA2695031A1 Novel substituted piperidones as hsp inducers |
| 01/08/2009 | CA2692502A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 01/08/2009 | CA2692412A1 Treatment for anxiety |
| 01/08/2009 | CA2692355A1 Production and purification of esters of polyunsaturated fatty acids |
| 01/08/2009 | CA2692253A1 Gamma secretase modulators |
| 01/08/2009 | CA2691844A1 Therapeutic compound |
| 01/08/2009 | CA2691704A1 4-imidazolines and their use as antidepressants |
| 01/08/2009 | CA2691638A1 Piperidine derivatives useful as orexin receptor antagonists |
| 01/08/2009 | CA2691575A1 Use of piperine and derivatives thereof for the therapy of neurological conditions |
| 01/08/2009 | CA2691373A1 3-aza-bicyclo[3.3.0]octane compounds |
| 01/08/2009 | CA2691107A1 Pharmaceutical combination of nsaid and prostaglandin compound |
| 01/08/2009 | CA2691082A1 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| 01/07/2009 | EP2011877A2 Conjugates for the modulation of immune responses |
| 01/07/2009 | EP2011800A2 Inhibitors of caspase |
| 01/07/2009 | EP2011796A1 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| 01/07/2009 | EP2011513A1 Therapeutic agents for alzheimer's disease and cancer |
| 01/07/2009 | EP2011499A2 Pyrrolo[2,3d]Pyrimidine compositions and their use |
| 01/07/2009 | EP2011498A1 Brain function-improving agent, and functional food containing the improving agent |
| 01/07/2009 | EP2011497A1 Agent exhibiting a neurotropic, neuromodulator, cerebrovascular and anti- stroke activity |
| 01/07/2009 | EP2011495A1 Use of piperine and derivatives thereof for the therapy of neurological conditions |
| 01/07/2009 | EP2011491A1 Anticonvulsive pharmaceutical compositions |
| 01/07/2009 | EP2011488A1 Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process |
| 01/07/2009 | EP2011485A2 Once-a-day oxycodone formulations |
| 01/07/2009 | EP2010536A1 Imidazo [1, 2-b]pyridazines, their processes of preparation and their use as gaba receptor ligands |
| 01/07/2009 | EP2010535A1 Thioxanthine derivatives and their use as inhibitors of mpo |
| 01/07/2009 | EP2010534A1 Thioxanthine derivatives and their use as inhibitors of mpo |